Perspective · 10 Sep 2026
Conference abstractPublished 2 Nov 2017
Development and characterization of a microparticulate vaccine formulation for metastatic breast cancer
Mercer University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Breast cancer is the most fatal form of cancer in females. Even with early diagnosis, 20% of women still develop metastases. Immunotherapy is being explored to provide a better treatment option, as current therapies against breast cancer are mostly invasive and pose numerous adverse effects. With this in mind, our purpose has been to formulate and evaluate a micro particulate therapeutic vaccine to provide a new line of therapy for metastatic breast cancer. Murine breast cancer cell line 4T1 was used as source of antigens. Vaccine microparticles were prepared by encapsulating 4T1 tumor associated antigens in cellulose polymer using spray dryer technology. Total protein concentration of the whole cell lysate was determined by Bio-Rad total protein assay. In vitro characterization of microparticles was conducted. In vitro innate immune response was determined by performing nitric oxide assay. Expression of surface co-stimulatory molecules on dendritic cells treated with vaccine microparticles and other controls were determined by flow cytometer using different markers (CD40, CD80, MHCI and MHC II). The yield of the microparticulate vaccine, following spray drying was 80Ã?±5% w/w. Total protein content of whole cell lysate was 3.48Ã?±1.25 mg/mL. The particle size was 1-4 Ã?µm. Zeta potential was -7Ã?±2 mV. There were significantly higher amount of nitric oxide released in the supernatant of cells exposed to vaccine microparticles compared to blank microparticles. CD40, MHC II and CD80, MHC I expression were significantly higher in the vaccine microparticles group compared to blank microparticles and vaccine suspension group.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Rokon Uz Zaman”
- BylineArticles whose byline prints “Rikhav P Gala”
- BylineArticles whose byline prints “Nihal S Mulla”
- BylineArticles whose byline prints “Martin J D’Souza”

